Operating Lease, Right-of-Use Asset of Protalix BioTherapeutics, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Protalix BioTherapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Protalix BioTherapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $7,810,000, a 38% increase year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Protalix BioTherapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $7,810,000 +$2,165,000 +38% 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $4,997,000 -$733,000 -13% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $5,225,000 -$654,000 -11% 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $5,430,000 -$479,000 -8.1% 31 Dec 2024 10-Q 13 Nov 2025 2025 Q3
Q3 2024 $5,645,000 -$270,000 -4.6% 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $5,730,000 -$76,000 -1.3% 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 $5,879,000 +$677,000 +13% 31 Mar 2024 10-Q 10 May 2024 2024 Q1
Q4 2023 $5,909,000 +$822,000 +16% 31 Dec 2023 10-K 17 Mar 2025 2024 FY
Q3 2023 $5,915,000 +$1,061,000 +22% 30 Sep 2023 10-Q 06 Nov 2023 2023 Q3
Q2 2023 $5,806,000 +$1,037,000 +22% 30 Jun 2023 10-Q 07 Aug 2023 2023 Q2
Q1 2023 $5,202,000 +$299,000 +6.1% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $5,087,000 +$127,000 +2.6% 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $4,854,000 -$391,000 -7.5% 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $4,769,000 -$637,000 -12% 30 Jun 2022 10-Q 15 Aug 2022 2022 Q2
Q1 2022 $4,903,000 -$587,000 -11% 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $4,960,000 -$607,000 -11% 31 Dec 2021 10-K 27 Feb 2023 2022 FY
Q3 2021 $5,245,000 -$455,000 -8% 30 Sep 2021 10-Q 15 Nov 2021 2021 Q3
Q2 2021 $5,406,000 -$271,000 -4.8% 30 Jun 2021 10-Q 16 Aug 2021 2021 Q2
Q1 2021 $5,490,000 -$223,000 -3.9% 31 Mar 2021 10-Q 14 May 2021 2021 Q1
Q4 2020 $5,567,000 -$110,000 -1.9% 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $5,700,000 -$64,000 -1.1% 30 Sep 2020 10-Q 29 Oct 2020 2020 Q3
Q2 2020 $5,677,000 -$179,000 -3.1% 30 Jun 2020 10-Q 10 Aug 2020 2020 Q2
Q1 2020 $5,713,000 -$131,000 -2.2% 31 Mar 2020 10-Q 01 Jun 2020 2020 Q1
Q4 2019 $5,677,000 +$5,677,000 31 Dec 2019 10-K 30 Mar 2021 2020 FY
Q3 2019 $5,764,000 30 Sep 2019 10-Q 07 Nov 2019 2019 Q3
Q2 2019 $5,856,000 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 $5,844,000 31 Mar 2019 10-Q 06 May 2019 2019 Q1
Q4 2018 $0 31 Dec 2018 10-K 12 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.